In a phase 1-11 study, nine patients with myelodysplastic syndromes and concomitant severe transfusion-dependent cytopenias were treated with recombinant human interleukin-3 (rhlL-3) to improve hematopoietic function. Doses of rhlL-3 ranged from 260 pg/m2 to 500 pg/m2 and were given as daily subcutaneous bolus injections for 15 days. Blood leucocyte counts increased 1.3-to 3.6-fold in all nine patients, including neutrophils, eosinophils, lymphocytes, basophils, and monocytes. The mean absolute neutrophil counts increased from 1,35O/pL (range, 150 to 2,420) to 2,66O/pL (range, 300 to 9,380) (P < .05) immediately after the end of rhlL-3 therapy and to a maximum count of 4,096IpL (range, 350 to 10.820) (P < .01). Platelet responses were seen in two of four profoundly thrombocy-YELODYSPLASTIC syndromes (MDS) are charac-
In a phase 1-11 study, nine patients with myelodysplastic syndromes and concomitant severe transfusion-dependent cytopenias were treated with recombinant human interleukin-3 (rhlL-3) to improve hematopoietic function. Doses of rhlL-3 ranged from 260 pg/m2 to 500 pg/m2 and were given as daily subcutaneous bolus injections for 15 days. Blood leucocyte counts increased 1.3-to 3.6-fold in all nine patients, including neutrophils, eosinophils, lymphocytes, basophils, and monocytes. The mean absolute neutrophil counts increased from 1,35O/pL (range, 150 to 2,420) to 2,66O/pL (range, 300 to 9,380) (P < .05) immediately after the end of rhlL-3 therapy and to a maximum count of 4,096IpL (range, 350 to 10.820) (P < .01). Platelet responses were seen in two of four profoundly thrombocy-YELODYSPLASTIC syndromes (MDS) are charac-M terized by progressive refractory cytopenias with cellular dysfunction and defective myeloid maturation involving at least two and generally three hematopoietic cell lineages.' Although 10% to 40% of these patients eventually develop acute leukemia, infections and thrombocytopenic bleeding are the most frequent causes of death.* Treatment of anemia and severe thrombocytopenia still depends mainly on red blood cell and platelet transfusions; treatment with cytotoxic or differentiation-inducing agents, eg, low-dose cytosine arabinoside, vitamin D,, retinoic acid, or interferon alfa, has been only partly su~cessful.~ With the recent availability of recombinant hematopoietic colony-stimulating factors (CSFs), stimulation of hematopoiesis in vivo has evolved as a new, potentially efficacious treatment modality. The feasibility of this approach is supported by several clinical studies showing that the two distinct CSFs, granulocyte-macrophage CSF (GM-CSF) and granulocyte CSF (G-CSF), can indeed elevate total leukocyte counts in patients with myelodysplastic syndromes."" However, improvements in neutrophil counts were only transient, and amelioration of erythropoiesis and thrombopoiesis were observed only ~poradically.~ Interleukin-3 (IL-3) belongs to a family of glycoprotein hormones responsible for regulating hematopoietic and immune functions." IL-3 promotes the survival, proliferation, and development of multipotential hematopoietic stem cdls and of committed progenitor cells of the granulocyte/ macrophage, erythroid, eosinophil, megakaryocyte, mast cell, and basophilic lineage~.l~-'~ In addition, IL-3 enhances myeloid end cell functions such as phagocytosis, antibodydependent cellular cytotoxicity, and metabolism of eosinophilsI6 but not neutrophil^,'^ as well as monocyte cytotoxicity."
Its range of activities is broader than that of the other C S F S . '~, '~,~~ In particular, it appears to be a more potent stimulator of megakaryocytopoiesis?' and of ontogenetically very early hematopoietic progenitor cells. '4 Preclinical studies have shown that IL-3 effectively stimulates myelopoiesis, erythropoiesis, and thrombopoiesis in several murine and nonhuman primate On the topenic patients, resulting in discontinuation of platelet transfusion. The requirements for red blood cell transfusion temporarily improved in one patient. Stimulation of plasma cells was evident by a significant increase in serum IgM and IgA levels. Mild side effects (fever, headache, local erythema, and bone pain) were observed in some patients, while transient thrombocytopenia developed in two patients. Disease progression with an increase in blast cells was seen in one patient. These results suggest that rhlL-3 is effective in stimulating hematopoiesis of all lineages in patients with myelodysplastic syndromes and may produce at least short-term hematologic improvement. 0 1990 by The American Society of Hematology.
basis of these data and the availability of sufficient quantities of recombinant human IL-3 (rhIL-3) produced by recombinant DNA we have treated nine patients with myelodysplastic syndromes as part of a phase 1-11 study in patients with cancer, bone marrow failure, or both. Our data demonstrate the capacity of rhIL-3 to stimulate myelopoiesis and, to a lesser degree, thrombopoiesis and erythropoiesis at dose levels well-tolerated by these patients.
METHODS
In a phase 1-11 study, nine patients with MDS and transfusion-dependent cytopenia were treated with rhIL-3: three men and six women, ranging in age from 32 to 80 years (median, 62 years) ( Table 1 ). According to the French-American-British (FAB) Cooperative Group criteria for myelodysplastic syndromes," six patients had a refractory anemia (RA) (four of whom had a deletion of the long arm of chromosome 5 [Sq-syndrome] ) and three patients had a refractory anemia with excess of blasts in the bone marrow (RAEB). None of the patients was a candidate for bone marrow transplantation or conventional high-dose chemotherapy. The patients did not receive any form of therapy other than transfusions for at least 4 weeks before entry. Two patients had already been treated 456 GANSER ET AL with recombinant GM-CSF at 6 weeks to 1 year before entering the present trial, without any lasting improvements of peripheral blood counts. Eligibility criteria included a performance status of more than 50% (Karnofsky-Scale), life expectancy of more than 3 months, preserved hepatic, renal, cardiac, and hemostaseologic function, and absence of clinically apparent allergies or bronchoalveolar disorders. The study was approved by the local ethics committee. Informed written consent was obtained from the patients before rhIL-3 therapy.
The cDNA of rhIL-3 was isolated from human peripheral blood lymphocytes and the gene product expressed in yeast. 30 The molecular weight was in the range of 14 to 16 Kd. The rhIL-3 used in this study was produced and provided by Immunex/Behringwerke AG (Seattle, WA and Marburg, FRG) and had a specific activity of greater than 1 x lo7 units/mg protein in a bone marrow proliferation assay. Sterility, pyrogenicity, general safety, and purity studies met the Office of Biologics standard. No endotoxin was measurable with the limulus amebocyte lysate assay (less than 10 pg/mg protein).
rhIL-3 was given by subcutaneous bolus injection daily for I5 days. The dose levels at which the patients entered the study were 250 pg/m2 and 500 pg/m2. Patients were monitored daily, and all constitutional symptoms were recorded. Before and during the study, patients were regularly monitored by means of complete history and physical examination and laboratory tests, including a complete blood count, differential and reticulocyte
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counts, a chemistry profile, coagulation profile, and urinalysis. An electrocardiogram and chest X-ray were done before the study and after the final dose. Bone marrow aspirates and biopsy specimens were processed according to conventional methods and evaluated before and after the treatment cycle for cellularity and megakaryocyte content by an independent hematopathologist. Chromosome studies were done on marrow samples obtained before and after the treatment.
Toxicity was graded according to the World Health Organization (WHO) riter ria.^' Dose limiting toxicity was generally defined as toxicity of grade 3 or higher by WHO criteria. Red blood cell concentrates were given if the hemoglobin level dropped below 8 g/dL or if there were symptoms related to anemia. Platelet transfusions were only given in cases of bleeding. Antipyretics were not given unless the body temperature rose to greater than 39OC. The Wilcoxon signed rank test for paired data was used to test for statistical significance of the observed changes after treatment with rhIL-3.
RESULTS
Pronounced responses of the leukocyte counts to rhIL-3 injections were observed with significant increases in total leukocytes, neutrophils, eosinophils, basophils, lymphocytes, and monocytes (Fig 1, Table 2 ). Neutrophilic granulocytes increased in all nine patients from a mean of 1,35O/pL to 23 days) (P < .02), being most pronounced in the patients with the 5q-syndrome (Fig 2) . However, side effects related to histamine release were not seen. The response of the platelets and reticulocytes was diverse. In one patient (patient F13), a substantial increase of reticulocyte counts was associated with a transient reduction of transfusion requirements from 8 units to 2 units of red blood cells per month, while in six patients the degree of anemia was unchanged. In contrast, in two patients with 5q-syndrome (patients F12 and F14), erythropoiesis was markedly diminished after rhIL-3 treatment, resulting in increased transfusion requirements.
Increases in platelet counts, accompanied by a reduced bleeding tendency, were seen in two patients with profound thrombocytopenia (patients F29 and F30) (Fig 3) , allowing a discontinuation of platelet transfusions for more than 4 months. However, in the four patients with the 5q-syndrome and normal platelet counts, platelet numbers decreased during the first 10 days of rhIL-3 treatment, with 
Fig 3. Effect of rhlL-3 on the platelet counts in two thrombocytopenic patients with RAE6 (A) and in four patients with 5q-syndrome (B).
subsequent recovery above pretreatment levels in three of these patients (Fig 3) . In one patient (patient F15), platelet counts decreased, although reversibly, to below 20,00O/pL (patient F15). Three patients (F13, F29, and F30) who had responded to the first course of rhIL-3 with reduced requirements for platelet or red blood cell transfusions, received additional cycles of rhIL-3. A repeated response was observed only in patient F29, who did not respond again after a third cycle of rhIL-3 (Table 3) . Transient increases in circulating blast cells occurred in two patients (patients F28 and F36), not exceeding 1% in the differential count. Maximum blast cell counts in the peripheral blood were observed after a median of 15.5 days (range, 8 to 18). However, in only one patient (F25) was the increase in circulating blast cells sustained and paralleled by a rise of blast cells in the bone marrow.
Bone marrow samples obtained in all patients before and after the treatment cycles showed increases in cellularity in seven of the patients, as well as in the M/E-ratio (P i .05) ( Table 4 ). An increase in cellularity and in the degree of fibrosis was observed in two patients with increased marrow fiber content before treatment with rhIL-3 (Fig 4) . The incidence of eosinophils increased in all patients (P < .Ol), while basophilia was only induced in the four patients with the 5q-syndrome (a 4.6-to 6-fold increase). Increases in megakaryocytes occurred in four patients. Megakaryocyte morphology was unchanged, with persistent hypolobulation of the nucleus in the patients with the 5q-syndrome. Recombinant human IL-3 had no effect on the differentiation ratio of mature myeloid cells (myelocytes plus metamyelocytes plus neutrophils) to immature myeloid cells (myeloblasts plus promyelocytes), with a mean of 4.15 (range, 0.77 to 7.78) before and 7.82 (range, 0.96 to 33) after treatment. The percentage of blast cells in the bone marrow increased significantly from 2% to 26% in one patient while on study. Neither lymphocyte nor plasma cell frequencies changed significantly.
Toxicity of the treatment schedule was generally mild (Table 5 ). Mild local Bone marrow changes.
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erythema at the site of subcutaneous injection of rhIL-3 was observed in two patients. Fever occurred in all patients. Fever above 38OC closely related to the application of rhIL-3 and lasting 2.5 to 16 hours was observed during the initial 1 to 4 days of the treatment cycle in six patients and subsided thereafter without any specific therapy. In one patient, peak temperatures above 39OC were observed during the first 2 days of the cycle, while in two patients fever above 4OoC occurred on day 1 of treatment. In the latter two patients, fever episodes had already been present before administration of rhIL-3. Infectious organisms could not be identified. Fever was accompanied by stiffness of the neck and headache in three patients, leading to dosage reduction from 500 pg/m2 to 250 pg/m2 in one patient (F30). Moderate bone pain was observed in two patients. A drop in platelet counts below 20,OOO/pL was seen on day 10 in one patient (F15) treated with 500 pg rhIL-3/m2, necessitating discontinuation of therapy. Thrombocytopenia in this patient was accompanied by intragluteal hematoma requiring red blood cell and platelet transfusion. The patient recovered completely, and the platelet count increased to pretreatment values within 2 weeks after discontinuation of rhIL-3 therapy. Development of thrombocytopenia below 50,000/pL was observed in another patient (F13) immediately after the end of the treatment cycle on day 16 with complete recovery within the following 2 weeks. One patient with R A (F25) exhibited progression to RAEB with transformation to acute leukemia while on study. She died of respiratory failure of unknown cause. The chest X-ray revealed no infiltrations. A postmortem examination was refused. One episode of bacteremia in 
DISCUSSION
Nine patients with myelodysplastic syndromes and longlasting cytopenias requiring frequent transfusions of red blood cells and platelets were treated with rhlL-3 in an attempt to restore hematopoiesis and to decrease the risk of infection and bleeding. Treatment with rhlL-3 induced an increase in bone marrow cellularity and in granulocytic elements. resulting in a rise of circulating leukocytes. The increase in neutrophil counts. which was substantial in all but two patients, was not dose-related but varied between the patients with regard to peak levels and the time until the peak values were reached. The leukocyte response to rhlL-3 was comparable to that observed in patients with solid tumors but normal hematopoiesis who were also treated with rhlL-3. In the latter patients. a clearly dose-related response of leukocyte counts was observed within the given dose range from 60 pg/m' to 500 pg/m'. with a 2.4-fold and 3.0-fold increase at dosages of 250 pg/m' and 500 pg/m'. respectively. Therefore, the intrinsic stem cell defect in patients with myelodysplasia might only allow an abnormal maturation of the multipotent and lineage-committed progenitor cells in response to hematopoietic cytokines." However. rhlL-3 a p pears to beable to inducean expansion of the neutrophil pool. both in the bone marrow and in the peripheral blood. which with increased serum levels of IgM and IgA could further contribute to improved host defense. Thus, only one episode of bacteremia occurred during the study. Prospective trials will have to be carried out to study the efficacy of rhlL-3 treatment in preventing infections. The increase in platelet and reticulocyte counts induced by rhlL-3 was only moderate in comparison to the findings in patients with normal hematopoiesisor withsecondary hematopoetic failure. In patients with normal hematopoiesis. a doubling of the platelet counts occumd afker treatment with rhlL-3 at 250 pg/m'. while in three of four ~v e r e l y thrombocytopenic patients with secondary hematopoietic failure, platelet counts recovered from below 20.000/pL to above 50.000/pL after rhlL-3. Nevertheless, two of four profoundly thrombocytopenic. transfusiondependent patients had a clinical benefit from an albeit modest platelet increase in that they did not require platelet transfusions for a period of 4 months. Therefore. with regard to its action on thrombopoiesis, rhlL-3 appears to be at least as efficient as both GM-CSP" and G-CSF."." Whether I L 3 plays a role in the development of bone marrow fibrosis. as suggested by a reversible increase in bone marrow fiber content in two patients. has to be carefully studied in future clinical trials.
The most pronounced increases in neutrophils, eosinophils, and basophils after treatment with rhlL-3 were Seen in patients with the 5q-syndrome. In comparison to the previously reported modest response of granulocytes in patients with 5q-anomaly to in vivo therapy with GM-CSF.'.6 rhlL-3 may be superior, but controlled trials have not yet been done. Only limited data in a small number of patients are available. The rather modest increases in platelet counts and the transient deterioration of erythropoiesis in two of four of these patients reflect the previously described significant reduction in the number of erythroid colonies obtained from 5q-marrow with normal in vitro growth of granulocyte-macrophage progenitor ~e l l s .~~,~' The lack of a stimulation and morphologic normalization of erythropoiesis and megakaryopoiesis by IL-3 indicates that replacement therapy with this cytokine alone is as insufficient to improve this disorder as has been GM-CSF.ss6
Of the few side effects, the most uncomfortable to the patients were headache and stiffness of the neck, which were partly reversible with analgesics and disappeared after discontinuation of rhIL-3 therapy. The mechanism of neck stiffness, which has not been reported in patients treated with GM-CSF or G-CSF, is not understood, but could be related to the release of mediators, eg, kinins, from mature cells. Despite an increase in basophils, side effects related to histamine were not observed. In one patient with RA, the proliferative effect of rhIL-3, which is a potent stimulator of leukemic blast cells in vitro:' resulted in an increase of blast cells in the bone marrow and peripheral blood. This patient differed from the other patients by a secondary nature of MDS strongly suggested by complex chromosomal translocations and a 7-year-long daily administration of azathioprin as an immunosuppressant for presumed encephalomyelitis. In the remaining patients, there were no increased blast numbers in the bone marrow or in the peripheral blood, indicating that the malignant cell populations remained under differentiative control. However, whether the blast cells of patients with secondary MDS or complex chromosomal translocation act differently in comparison to those from the other patients can only be clarified in larger trials.
In conclusion, IL-3 appears to be of value in increasing neutrophil counts, as well as platelet counts, in profoundly thrombocytopenic patients with myelodysplastic syndromes. Since erythropoiesis is rarely improved, combination of IL-3 with a maturation factor of erythropoiesis, eg, erythropoietin, should be considered for future trials.
